MedTrace Logo

Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas

NCT02771301 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-05-13

No results posted yet for this study

Summary

This trial is aimed at evaluating the safety and efficacy of IDH1R132H-DC vaccine in glioma with IDH1R132H mutation.

Conditions

Interventions

BIOLOGICAL

dendritic cells

Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Hebei Yanda Hospital

    lead OTHER

Principal Investigators

  • Nan Ji, PhD · Beijing Tiantan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02771301 on ClinicalTrials.gov